Literature DB >> 1687501

Steric aspects of agonism and antagonism at beta-adrenoceptors: synthesis of and pharmacological experiments with the enantiomers of formoterol and their diastereomers.

J Trofast1, K Osterberg, B L Källström, B Waldeck.   

Abstract

The enantiomers of formoterol (R;R and S;S) and their diastereomers (R;S and S;R) were synthesized and purified using a new procedure which required the preparation of the (R;R)- and (S;S)-forms of N-(1-phenylethyl)-N-(1-(p-methoxyphenyl)-2-propyl)-amine as important intermediates. The enantiomeric purity obtained was greater than 99.3%, usually greater than 99.7%. The four stereoisomers were examined with respect to their ability to interact in vitro with beta-adrenoceptors in tissues isolated from guinea pig. The effects measured were (1) relaxation of the tracheal smooth muscle (mostly beta 2), (2) depression of subtetanic contractions of the soleus muscle (beta 2), and (3) increase in the force of the papillary muscle of the left ventricle of the heart (beta 1). All enantiomers caused a concentration-dependent and complete relaxation of the tracheal smooth muscle which was inhibited by propranolol. The order of potency was (R;R) much greater than (R;S) = (S;R) greater than (S;S). There was a 1,000-fold difference in potency between the most and the least potent isomer. The presence of the (S;S)-isomer did not affect the activity of the (R;R)-isomer on the tracheal smooth muscle. Also on the skeletal and cardiac muscles (R;R)-formoterol was more potent than its (R;S)-isomer. The selectivity for beta 2-adrenoceptors appeared to be slightly higher for the (R;R)-isomer than for the (R;S)-isomer. The potency of the (S;R)- and (S;S)-isomers on the papillary muscle was too low to be determined accurately.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687501     DOI: 10.1002/chir.530030606

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  8 in total

1.  Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.

Authors:  Peter Molenaar; Lu Chen; William A Parsonage
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

2.  Chiral Switch Drugs for Asthma and Allergies: True Benefit or Marketing Hype.

Authors:  Kathryn Blake; Hengameh Raissy
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2013-09       Impact factor: 1.349

3.  Stereoselective glucuronidation of formoterol by human liver microsomes.

Authors:  M Zhang; J P Fawcett; J M Kennedy; J P Shaw
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

4.  Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human.

Authors:  Mei Zhang; J Paul Fawcett; John P Shaw
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

5.  The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro.

Authors:  B L Källström; J Sjöberg; B Waldeck
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

6.  Effects of formoterol on contraction and Ca2+ signaling of mouse airway smooth muscle cells.

Authors:  Philippe Delmotte; Michael J Sanderson
Journal:  Am J Respir Cell Mol Biol       Date:  2009-06-05       Impact factor: 6.914

7.  Differential effects of formoterol on thrombin- and PDGF-induced proliferation of human pulmonary arterial vascular smooth muscle cells.

Authors:  Elena A Goncharova; Irene S Khavin; Dmitry A Goncharov; Vera P Krymskaya
Journal:  Respir Res       Date:  2012-11-27

Review 8.  Role of arformoterol in the management of COPD.

Authors:  Paul King
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.